- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Population Pharmacokinetics of Necitumumab in Cancer Patients ; day:30 ; month:9 ; year:2016 ; pages:1-10
Clinical pharmacokinetics ; (30.9.2016), 1-10
- Creator
-
Long, Amanda
- Contributor
-
Chigutsa, Emmanuel
Wallin, Johan
SpringerLink (Online service)
- DOI
-
10.1007/s40262-016-0452-x
- URN
-
urn:nbn:de:1111-201610319673
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Long, Amanda
- Chigutsa, Emmanuel
- Wallin, Johan
- SpringerLink (Online service)
Other Objects (12)
Population pharmacokinetics of bevacizumab in cancer patients with external validation
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Population pharmacokinetics of cefotaxime in intensive care patients
Population pharmacokinetics of meropenem in critically ill patients
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
Population pharmacokinetics of haloperidol in terminally ill adult patients
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
Population pharmacokinetics of bevacizumab in cancer patients with external validation
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Population pharmacokinetics of cefotaxime in intensive care patients
Population pharmacokinetics of meropenem in critically ill patients
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
Population pharmacokinetics of haloperidol in terminally ill adult patients
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
Population pharmacokinetics of bevacizumab in cancer patients with external validation
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Population pharmacokinetics of cefotaxime in intensive care patients
Population pharmacokinetics of meropenem in critically ill patients
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
Population pharmacokinetics of haloperidol in terminally ill adult patients
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors